Regulus Therapeutics (RGLS) Receives News Impact Score of 0.57
Press coverage about Regulus Therapeutics (NASDAQ:RGLS) has trended very positive on Tuesday, according to Accern. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regulus Therapeutics earned a media sentiment score of 0.57 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Regulus Therapeutics Inc. (RGLS) Earns “Ourperform” Rating from Wedbush (americanbankingnews.com)
- Regulus Therapeutics Inc (RGLS) Showing Negative Momentum in the Technicals – Evergreen Caller (evergreencaller.com)
- Regulus Therapeutics’ (RGLS) Hold Rating Reaffirmed at Needham & Company LLC (americanbankingnews.com)
- Regulus Therapeutics Inc. (RGLS) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS (americanbankingnews.com)
Several research analysts have recently issued reports on RGLS shares. BMO Capital Markets restated a “hold” rating on shares of Regulus Therapeutics in a report on Monday, May 15th. ValuEngine cut shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Chardan Capital lowered their target price on shares of Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating for the company in a report on Tuesday, June 13th. Wedbush restated an “ourperform” rating and issued a $6.00 target price on shares of Regulus Therapeutics in a report on Tuesday, June 13th. Finally, Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. Regulus Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $3.58.
Shares of Regulus Therapeutics (NASDAQ RGLS) traded down 3.7134% during mid-day trading on Tuesday, reaching $0.9516. 515,197 shares of the company were exchanged. Regulus Therapeutics has a 12 month low of $0.86 and a 12 month high of $3.81. The company’s 50-day moving average is $1.00 and its 200 day moving average is $1.34. The firm’s market capitalization is $50.61 million.
Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.10. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Analysts predict that Regulus Therapeutics will post ($1.10) EPS for the current year.
In other Regulus Therapeutics news, Director William H. Rastetter bought 274,725 shares of the stock in a transaction on Tuesday, July 25th. The stock was purchased at an average price of $0.91 per share, for a total transaction of $249,999.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Daniel R. Chevallard bought 54,945 shares of the stock in a transaction on Tuesday, July 25th. The shares were acquired at an average price of $0.91 per share, with a total value of $49,999.95. Following the purchase, the chief financial officer now owns 59,415 shares of the company’s stock, valued at $54,067.65. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 549,450 shares of company stock valued at $500,000. 4.80% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/08/regulus-therapeutics-rgls-getting-very-positive-news-coverage-study-finds-updated-updated-updated.html.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Stock Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related stocks with our FREE daily email newsletter.